Polarized Dendritic Cell (aDC1) Based Treatment
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Polarized Dendritic Cell (aDC1) Based Treatment, covering 2026-02-25 to 2026-02-25. Get the full timeline:
Most recent: Clinical Trial Update: Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma [Phase 2]